Currently, mammographic breast screening is a widespread method of early diagnosis of asymptomatic forms of this malignant tumor in many countries, although mammography has a number of limitations and a comparative cost of breast cancer treatment. Thus it is emerging to develop and implement new effective approaches to breast cancer screening, as well as research into new strategies for early diagnostics and screening of breast cancer that have sufficiently high sensitivity and specificity, are economically acceptable and do not require significant budget expenditures. The use of serum biomarkers as an additional method for early diagnostics of breast cancer may become a new promising cost-effective tool for practical oncology. In my presentation, I will demonstrate the results of the clinical blind study on the combined use of two biomarkers, CA 15-3 and CA-62, for Stage I breast cancer detection, using an elevated cutoff value to eliminate false positives among healthy women. The results obtained demonstrate that a combination of CA15-3 with CA-62 yields 75% Sensitivity at 100% Specificity for DCIS and Stage I breast cancer detection, which has a potential to be integrated into existing screening programs.

Alexander Boroda is a Research fellow and clinical oncologist at I.M. Sechenov First Moscow State Medical University, Department of Personalized Oncology specialist (clinician-researcher). 19.5-year experience in oncology, participation in International Clinical and Epidemiological Studies. Internship and cooperation: European School of Oncology, Milan (Italy), International Agency for Research on Cancer (IARC), Lyon (France); Oxford University (UK), European Society For Medical Oncology, Lugano (Switzerland). Publications in leading international scientific journals with a high impact factor, such as "The Lancet", "International Journal of Epidemiology", "Frontiers in Oncology" and several other reputed journals.